MALVERN, Pa., Nov. 11, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the third quarter ended September 30, 2020.

Excerpt from:
TELA Bio Announces Third Quarter 2020 Financial Results

WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Frank Watanabe, President and CEO, will present a corporate overview during the Stifel 2020 Virtual Healthcare Conference taking place November 16-18, 2020.

Read this article:
Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET

Read this article:
Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results

FLORHAM PARK, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.

See original here:
PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update

Data shows CPI-006 provided enhanced and prolonged polyclonal humoral immunity to SARS-CoV-2

Here is the original post:
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting

PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis

See more here:
Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCONx Conference.

See the article here:
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Conference call to be held at 4:30 p.m. Eastern Time today

Read more here:
OpGen Reports Third Quarter 2020 Financial Results and Provides Business Update

- Conference Call Scheduled November 11, 2020 at 4:30 p.m. ET - - Conference Call Scheduled November 11, 2020 at 4:30 p.m. ET -

Read the original:
Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results

Submitted a premarket approval (PMA) to the FDA for LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN)

See the rest here:
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and December:

Continue reading here:
Retrophin to Present at Upcoming Investor Conferences

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in November:

See the original post:
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences

– Event will provide an overview of how Ascendis is applying its TransCon™ technology platform and its unique algorithm for product innovation to the therapeutic area of oncology –

See original here:
Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20

ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview and update, as well as host investor meetings, at the following virtual investor conferences in November 2020.

Read the original:
Supernus to Present at Two November Investor Conferences

GHENT, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020.

Read more:
Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

MARSEILLE, France, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.

See the original post here:
Innate Pharma to Participate in upcoming investor conferences

COPENHAGEN, Denmark, November 12, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include additional indications – specifically, monkeypox and related orthopoxvirus infections and disease in adults 18 years of age and older determined to be at high risk for exposure.

Continue reading here:
Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox Viruses

Data presented support the potential of combining oncolytic virotherapy along with PM21-NK cell adoptive therapy against lung cancer

Continued here:
Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it plans to release 12-month data for Groups 1 through 4 evaluating durability of effect and continued safety and interim data of Groups 5 and 6 evaluating safety and efficacy at higher doses for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa (XLRP) on November 11, 2020. AGTC management will host a conference call and webcast with accompanying slides to review the data and provide a general update on the XLRP trial beginning at 8:00am Eastern Time on the same date.

View post:
AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing...

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020.

Read more from the original source:
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights